UPDATE SENSORION | Corporate, TP EUR6 |Game time for SENS-401
UPDATE SENSORION | Corporate, TP EUR6 |Game time for SENS-401The most well-balanced equity story in hearing loss
• Sensorion key investment highlights
• SENS-401 in Sudden sensorineural hearing loss (SSNHL)
• SENS-401 in Cisplatin-induced ototoxicity (CIO)
• Inner ear is the next big thing in gene therapy
• One of the broadest pipeline of inner ear gene tx
• Valuation
• We maintain our EUR6 TP
Sensorion SA is a France-based company principally engaged in the biopharmaceutical sector. The Company is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The Company develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.